Skip to main content
SpringerLink
Log in
Book cover

Hormonal Carcinogenesis II pp 167–175Cite as

Growth Factors in Endometrial Cancer

  • Conference paper

  • 62 Accesses

Abstract

Progressive tumor growth has been associated with neovascularization induced by an angiogenic factor(s) that the tumor secretes (1). Therefore, inhibition of neovascularization could be effective in suppressing tumor growth (2). The antiproliferative effects of progestins in human endometrial cancer cells have been demonstrated by several investigators. Previously, we reported that the growth of human endometrial adenocarcinoma cells in primary culture was significantly suppressed by medroxyprogesterone acetate (MPA) (3); a similar growth-inhibitory effect has been reported in a nude mouse system (4). We have suggested that the antiproliferative effect of progestin on adenocarcinoma cells is mediated through progestin receptors (PR) present in the cells (5). In contrast, using the rabbit cornea assay, Gross et al. have shown that MPA inhibits the angiogenesis induced by several tumors of laboratory animals (6). Recent studies have shown that human endometrial adenocarcinoma cells produce angiogenic factors (7). Although MPA seems to act directly on endometrial cancer cells to inhibit their growth, the present data suggest that its inhibition of angiogenesis may share the same mechanism by which it inhibits the growth of endometrial adenocarcinoma. In the present study, to gain further information on MPA’s mechanism of action in human endometrial cancer, we examined MPA’s effect on angiogenesis induced by adenocarcinoma. We also investigated the synthesis and secretion of angiogenic growth factor(s) in a human endometrial cancer cell line.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Folkman J, Klagsbrun M (1987) Angiogenic factors. Science 235:442–447.

    Article  PubMed  CAS  Google Scholar 

  2. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4–6.

    Article  PubMed  CAS  Google Scholar 

  3. Terakawa N, Ikegami H, Shimizu I et al (1988) Inhibitory effects of danazol and medroxyprogesterone acetate on [3H]thymidine incorporation in human endometrial cancer cells. J Steroid Biochem 31:131–135.

    Article  PubMed  CAS  Google Scholar 

  4. Zaino RJ, Satyaswaroop PG, Mortel R (1985) Hormonal therapy of human endometrial adenocarcinoma in a nude mouse model. Cancer Res 45:539–541.

    Google Scholar 

  5. Terakawa N, Hayashida M, Shimizu I (1987) Growth inhibition by progestins in a human endometrial cancer cell line with estrogen- independent progesterone receptors. Cancer Res 47:1918–1923.

    PubMed  CAS  Google Scholar 

  6. Gross J, Azizkhan RG, Biswas C (1981) Inhibition of tumor growth, vascularization, and collagenolysis in the rabbit cornea by medroxyprogesterone. Proc Natl Acad Sci USA 78:1176–1180.

    Article  PubMed  CAS  Google Scholar 

  7. Ishiwata I, Ishiwata C, Soma M (1988) Tumor angiogenic activity of gynecologic tumor cell lines on chorioallantoic membrane. Gynecol Oncol 29:87–93.

    Article  PubMed  CAS  Google Scholar 

  8. Jikihara H, Terada N, Yamamoto R (1992) Inhibitory effect of medroxyprogesterone acetate on angiogenesis induced by human endometrial cancer. Am J Obstet Gynecol 167:207–211.

    PubMed  CAS  Google Scholar 

  9. Kauppila AJI, Isotalo HE, Kivinen ST, Vihko RK (1986) Prediction of clinical outcome with estrogen and progestin receptor concentrations and their relationships to clinical and histopathological variables in endometrial cancer. Cancer Res 46:5380–5384.

    PubMed  CAS  Google Scholar 

  10. Gronroos M, Maenpaa J, Kangas R (1987) Steroid receptors and response of endometrial cancer to hormones in vitro. Ann Chir Gynecol 76:76–79.

    Google Scholar 

  11. Presta M, Maier JAM, Rusnati (1988) Modulation of plasminogen activator activity in human endometrial adenocarcinoma cells by basic fibroblast growth factor and transforming growth factor-β. Cancer Res 48:6384–6389.

    PubMed  CAS  Google Scholar 

  12. Fujimoto J, Fujita H, Hosoda S (1989) Effect of medroxy-progesterone acetate on secondary spreading of endometrial cancer. Invasion Metastasis 9:209–215.

    PubMed  CAS  Google Scholar 

  13. Gong Y, Anzai Y, Murphy LC (1991) Transforming growth factor gene expression in human endometrial adenocarcinoma cells: Regulation by progestins. Cancer Res 51:5476–5481.

    PubMed  CAS  Google Scholar 

  14. Ashino-Fuse H, Takano Y, Oikawa T (1989) Medroxy-progesterone acetate, an anti-cancer and anti-angiogenic steroid, inhibits the plasminogen activator in bovine endothelial cells. Int J Cancer 44:859–864.

    Article  PubMed  CAS  Google Scholar 

  15. Derynck R, Jarrett JA, Chen EY (1985) Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells. Nature 316:701–705.

    Article  PubMed  CAS  Google Scholar 

  16. Kondaiah P, Sands MJ, Smith JM (1990) Identification of a novel transforming growth factor-β (TGF-P5) mRNA in Xenopus laevis. J Biol Chem 265:1089–1093.

    PubMed  CAS  Google Scholar 

  17. Murray K, Haussler CA, Trookman NS (1987) Divergent effects of epidermal growth factor and transforming growth factors on a human endometrial carcinoma cell line. Cancer Res 47:4909–4914.

    Google Scholar 

  18. Knabbe C, Lippman ME, Wakefield LM (1987) Evidence that transforming growth factor p is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48:417–428.

    Article  PubMed  CAS  Google Scholar 

  19. Boyd JA, Kaufman DG (1990) Expression of transforming growth factor p, by human endometrial carcinoma cell lines: Inverse correlation with effects on growth rate and morphology. Cancer Res 50:3394–3399.

    PubMed  CAS  Google Scholar 

  20. Croxtall JD, Jamil A, Ayub M (1992) TGF-β stimulation of endometrial and breast-cancer cell growth. Int J Cancer 50:822–827.

    Article  PubMed  CAS  Google Scholar 

  21. Jikihara H, Ikegami H, Sakata M (1991) Epidermal growth factor attenuates cell proliferation by down-regulating transforming growth factor-β receptor in the osteoblastic cell line MC3T3-E1. Bone Mineral 15:125–136.

    Article  CAS  Google Scholar 

  22. Sakata N, Kurachi H, Ikegami H (1993) Autocrine growth mechanism by transforming growth factor (TGF)β1 and TGF-β1 receptor regulation by epidermal growth factor in a human endometrial cancer cell line IK-90. Int J Cancer 54:862–867.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Naoki Terakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Etiology and Prevention of Hormonal Cancers, Hormonal Carcinogenesis Laboratory, University of Kansas Cancer Center, Kansas City, Kansas, USA

    J. Jonathan Li Ph.D. (Professor of Pharmacology, Toxicology, and Therapeutics, Director) (Professor of Pharmacology, Toxicology, and Therapeutics, Director)

  2. Hormonal Carcinogenesis Laboratory, University of Kansas Cancer Center, Kansas City, Kansas, USA

    Sara Antonia Li Ph.D. (Associate Professor of Pharmacology, Toxicology, and Therapeutics) (Associate Professor of Pharmacology, Toxicology, and Therapeutics)

  3. Department of Medical Nutrition, Center for Biotechnology, NOVUM, Huddinge University Hospital, Huddinge, Sweden

    Jan-Åke Gustafsson M.D., Ph.D. (Professor and Chairman, Director) (Professor and Chairman, Director)

  4. Department of Molecular and Cell Biology, Cancer Research Center, University of California, Berkeley, California, USA

    Satyabrata Nandi Ph.D. (Professor of Cell and Development Biology) (Professor of Cell and Development Biology)

  5. Division of Cancer Etiology, Chemical and Physical Carcinogenesis Program, National Cancer Institute, Rockville, Maryland, USA

    Lea I. Sekely Ph.D. (Program Director) (Program Director)

  6. University of Kansas Medical Center, Kansas City, Kansas, USA

    J. Jonathan Li Ph.D. (Professor of Pharmacology, Toxicology, and Therapeutics, Director) & Sara Antonia Li Ph.D. (Associate Professor of Pharmacology, Toxicology, and Therapeutics) (Professor of Pharmacology, Toxicology, and Therapeutics, Director) &  (Associate Professor of Pharmacology, Toxicology, and Therapeutics)

  7. National Institutes of Health, Rockville, Maryland, USA

    Lea I. Sekely Ph.D. (Program Director) (Program Director)

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag New York, Inc.

About this paper

Cite this paper

Terakawa, N. (1996). Growth Factors in Endometrial Cancer. In: Li, J.J., Li, S.A., Gustafsson, JÅ., Nandi, S., Sekely, L.I. (eds) Hormonal Carcinogenesis II. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-2332-0_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-2332-0_19

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4612-7506-0

  • Online ISBN: 978-1-4612-2332-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation